Multispectral Refraction Topography, called MRT, which is the world’s FIRST peripheral refraction detection device, enables the personalized management of myopia to be practical and effective.
While technological advancements have revolutionized modern lifestyles, they have also intensified a global vision crisis—myopia, affecting billions worldwide, particularly acute in China. A key driver of this epidemic, peripheral hyperopic defocus, has long eluded clinical translation due to the absence of practical detection methods. Enter Multispectral Refraction Topography (MRT), a paradigm-shifting innovation redefining myopia management through “million-point peripheral refraction mapping in 2.5 seconds”.
By integrating multispectral imaging with AI-powered analytics, MRT captures high-resolution fundus images across diverse wavelengths, reconstructing a comprehensive refractive map without repositioning or repeated measurements. Clinically validated across 1,000+ Chinese medical institutions, this technology bridges laboratory research and real-world applications, generating over 200 academic papers, conference presentations, and posters, and enabling data-driven, personalized interventions.
Its breakthrough impact extends to therapeutics: leveraging MRT-derived datasets, China pioneered the world’s first defocus-optimized myopia-control lenses, achieving 72% reduction in myopia progression and 64% efficacy in axial elongation control—benchmarks unmatched by conventional solutions.
As the cornerstone of precision ophthalmology, MRT empowers clinicians to visualize peripheral defocus patterns, tailor treatment strategies, and advance multidimensional research. By transforming theoretical insights into actionable diagnostics and therapeutics, this technology heralds a new era of individualized myopia prevention.